Isentress 400mg film-coated tablets
raltegravir
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
If you are the parent of a child taking Isentress, please read this information carefully with your child.
Contents of the pack
What Isentress is
Isentress contains the active substance raltegravir. Isentress is an antiviral medicine that acts against the human immunodeficiency virus (HIV). This is the virus that causes acquired immune deficiency syndrome (AIDS).
How Isentress works
The virus produces an enzyme called HIV integrase, which helps the virus to enter the cells of the body and multiply. Isentress prevents this enzyme from working. When used with other medicines, Isentress can reduce the amount of HIV in the blood (this is called your “viral load”) and increase the number of CD4 cells (a type of white blood cell that plays an important role in keeping your immune system healthy to help fight infection). By reducing the amount of HIV in the blood, it can improve the functioning of your immune system. This means your body can better fight off infections.
When Isentress should be used
Isentress is used to treat patients who are infected with HIV. Your doctor has prescribed Isentress to help you control the HIV infection you have.
Do not take Isentress:
Warnings and precautions
Talk to your doctor, pharmacist or nurse before you start taking Isentress.
Remember that Isentress does not cure HIV infection. This means you can still get illnesses and infections related to HIV. You must keep seeing your doctor regularly while taking this medicine.
Mental health problems
Tell your doctor if you have a history of depression or mental health problems. Depression, including thoughts of suicide and suicidal behaviour, has been reported in some patients taking this medicine, especially in patients with a history of depression or mental health problems.
Bone problems
Some patients taking combination antiretroviral therapy may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone). The duration of combination antiretroviral therapy, the use of corticosteroids, alcohol consumption, severe immunosuppression, high body mass index, among others, can be some of the many risk factors for developing this disease. The signs of osteonecrosis are joint stiffness, pain and difficulty moving. If you experience any of these symptoms, contact your doctor.
Liver problems
Tell your doctor, pharmacist or nurse if you have had liver problems in the past, including hepatitis B or C. Your doctor may assess the severity of your liver disease before deciding if you can take this medicine.
Infections
If you notice any symptoms of infection, such as fever and/or feeling unwell, tell your doctor, pharmacist or nurse immediately. Some patients with advanced HIV infection and who have had previous opportunistic infections may experience signs and symptoms of inflammation from previous infections when they start taking HIV treatment. These symptoms are thought to be due to the improvement in the body’s immune response, enabling the body to fight infections that may have been present without causing symptoms.
In addition to opportunistic infections, autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also occur after you have started taking medicines for the treatment of your HIV infection. Autoimmune disorders may occur many months after the start of treatment. If you observe any symptoms of infection or other symptoms such as muscle weakness, weakness starting in the hands and feet and moving up towards the trunk of the body, palpitations, tremors or hyperactivity, tell your doctor immediately to receive the necessary treatment.
Muscle problems
Contact your doctor, pharmacist or nurse immediately if you notice unexplained muscle pain, tenderness or muscle weakness during treatment with this medicine.
Skin problems
Contact your doctor immediately if you develop a rash. Serious and potentially life-threatening skin reactions and allergic reactions have been reported in some patients taking this medicine.
Other medicines and Isentress
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including those obtained without a prescription.
Isentress may interact with other medicines.
Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take:
Taking Isentress with food and drinks
See section 3.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking any medicine.
Driving and using machines
Do not drive or operate machinery if you feel dizzy after taking this medicine.
Isentress contains lactose
This medicine contains lactose. If your doctor has told you that you have an intolerance to some sugars, contact them before taking this medicine.
Isentress contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per tablet, i.e. essentially “sodium-free”.
Always take this medicine exactly as your doctor, pharmacist or nurse has told you. Check with your doctor, pharmacist or nurse if you are not sure. Isentress must be used in combination with other medicines for HIV.
How much to take
Adults
The recommended dose is 1 tablet (400 mg) taken by mouth twice a day.
Use in children and adolescents
The recommended dose of Isentress is 400 mg taken by mouth twice a day for adolescents and children weighing at least 25 kg.
Do not chew, crush or break the tablets as this may affect the amount of medicine in your body. You can take this medicine with or without food or drinks.
Isentress is also available as a 600 mg tablet, chewable tablet and granules for oral suspension.
Do not switch between the 400 mg tablet, 600 mg tablet, chewable tablet or granules for oral suspension without first consulting your doctor, pharmacist or nurse.
If you take more Isentress than you should
Do not take more tablets than your doctor has recommended. If you take more tablets than recommended, contact your doctor.
If you forget to take Isentress
If you stop taking Isentress
It is important that you take Isentress exactly as your doctor has told you. Do not change the dose or stop taking this medicine without first consulting your doctor, pharmacist or nurse. Do not stop taking it because:
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Serious side effects– these are uncommon (may affect up to 1 in 100 people)
See a doctor immediately if you notice any of the following serious side effects:
See a doctor immediately if you notice any of the above serious side effects.
Common: the following side effects may affect up to 1 in 10 people
Uncommon: the following side effects may affect up to 1 in 100 people
Other side effects in children and adolescents
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Isentress composition
The active ingredient is raltegravir. Each film-coated tablet contains 400 mg of raltegravir (potassium).
The other ingredients are: lactose monohydrate, microcrystalline cellulose, anhydrous dibasic calcium phosphate, hypromellose 2208, poloxamer 407, sodium stearyl fumarate, and magnesium stearate. In addition, the coating contains the following inactive ingredients: polyvinyl alcohol, titanium dioxide, polyethylene glycol 3350, talc, red iron oxide, and black iron oxide.
Product appearance and container contents
The 400 mg film-coated tablet is oval in shape, pink in color, and has "227" engraved on one side.
Two pack sizes are available: packs of 1 bottle of 60 tablets and multipacks containing 3 bottles of 60 tablets each. The bottle contains a desiccant.
Only some pack sizes may be marketed.
Marketing authorization holder and manufacturer
Merck Sharp & Dohme B.V.
Waarderweg 39
2031 BN Haarlem
Netherlands
For further information on this medicinal product, contact the local representative of the marketing authorization holder:
Belgium/Belgique/Belgien MSD Belgium Tel: +32(0)27766211 dpoc_belux@msd.com | Lithuania UAB Merck Sharp & Dohme Tel: +370 5 2780 247 dpoc_lithuania@msd.com |
Luxembourg/Luxemburg MSD Belgium Tel: +32(0)27766211 dpoc_belux@msd.com | |
Czech Republic Merck Sharp & Dohme s.r.o. Tel: +420 233 010 111 dpoc_czechslovak@merck.com | Hungary MSD Pharma Hungary Kft. Tel: +36 1 888 5300 hungary_msd@merck.com |
Denmark MSD Danmark ApS Tel: +45 4482 4000 dkmail@msd.com | Malta Merck Sharp & Dohme Cyprus Limited Tel: 8007 4433 (+356 99917558) malta_info@merck.com |
Germany MSD Sharp & Dohme GmbH Tel: +49 (0) 89 20 300 4500 medinfo@msd.de | Netherlands Merck Sharp & Dohme B.V. Tel: 0800 9999000 (+31 23 5153153) medicalinfo.nl@merck.com |
Estonia Merck Sharp & Dohme OÜ Tel: +372 614 4200 dpoc.estonia@msd.com | Norway MSD (Norge) AS Tel: +47 32 20 73 00 medinfo.norway@msd.com |
Greece MSD Α.Φ.Ε.Ε. Tel: +30 210 98 97 300 dpoc_greece@merck.com | Austria Merck Sharp & Dohme Ges.m.b.H. Tel: +43 (0) 1 26 044 dpoc_austria@merck.com |
Spain Merck Sharp & Dohme de España, S.A. Tel: +34 91 321 06 00 msd_info@msd.com | Poland MSD Polska Sp. z o.o. Tel: +48 22 549 51 00 msdpolska@merck.com |
France MSD France Tel: +33 (0) 1 80 46 40 40 | Portugal Merck Sharp & Dohme, Lda Tel: +351 21 4465700 inform_pt@merck.com |
Croatia Merck Sharp & Dohme d.o.o. Tel: + 385 1 6611 333 croatia_info@merck.com | Romania Merck Sharp & Dohme Romania S.R.L. Tel: +40 21 529 29 00 msdromania@merck.com |
Ireland Merck Sharp & Dohme Ireland (Human Health) Limited Tel: +353 (0)1 2998700 medinfo_ireland@msd.com | Slovenia Merck Sharp & Dohme, inovativna zdravila d.o.o. Tel: +386 1 520 4201 msd.slovenia@merck.com |
Iceland Vistor ehf. Tel: + 354 535 7000 | Slovak Republic Merck Sharp & Dohme, s. r. o. Tel: +421 2 58282010 dpoc_czechslovak@merck.com |
Italy MSD Italia S.r.l. Tel: 800 23 99 89 (+39 06 361911) dpoc.italy@msd.com | Finland MSD Finland Oy Tel: +358 (0)9 804 650 info@msd.fi |
Cyprus Merck Sharp & Dohme Cyprus Limited Tel: 800 00 673 (+357 22866700) cyprus_info@merck.com | Sweden Merck Sharp & Dohme (Sweden) AB Tel: +46 77 5700488 medicinskinfo@msd.com |
Latvia SIA Merck Sharp & Dohme Latvija Tel: + 371 67025300 dpoc.latvia@msd.com |
Date of last revision of this leaflet:<{MM/AAAA}><{month AAAA}>.
Detailed information on this medicinal product is available on the European Medicines Agency website: https://www.ema.europa.eu.